Atherosclerosis
Volume 204, Issue 1 , Pages 66-72 , May 2009

A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-κB signaling

  • Peter Kanellakis

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • ,
  • Giovanna Pomilio

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • ,
  • Catherine Walker

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
    • ,
  • Alan Husband

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
    • ,
  • Jiu Li Huang

      Affiliations

    • Novogen Pty Ltd, North Ryde, NSW, Australia
    • ,
  • Paul Nestel

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • ,
  • Alex Agrotis

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • ,
  • Alex Bobik

      Affiliations

    • Baker Heart Research Institute, Melbourne, Victoria, Australia
    • Corresponding Author InformationCorresponding author at: Cell Biology Laboratory, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria, Australia. Tel.: +61 3 8532 1190; fax: +61 3 8532 1100.

Received 19 March 2008 ,Revised 29 August 2008 ,Accepted 1 September 2008.

References 

  1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  2. Lowe HC, Oesterles N, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol. 2002;39:183–193
  3. Abahji TN, Tato F, Rieger J, et al. Stenting of the superficial femoral artery after suboptimal balloon angioplasty: on-year results. Int Angiol. 2006;25:184–189
  4. Wong J, Rauhoft C, Dilley DJ, Agrotis A, Jennings GL, Bobik A. Angiotensin converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates their proliferation. Circ. 1997;96:1621–1640
  5. Agrotis A, Kanellakis P, Kostolias G, et al. Proliferation of neointimal smooth muscle cells after vessel injury. Dependency on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J Biol Chem. 2004;279:42221–42229
  6. Kanellakis P, Nestel P, Bobik A. Angioplasty-induced superoxide anions and neointimal hyperplasia in the rabbit carotid artery: suppression by the isoflavone trans-tetrahydrodiadzein. Atherosclerosis. 2004;176:63–72
  7. Dourron HM, Jacobson GM, Park JL, et al. Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am J Physiol. 2005;288:H946–H953
  8. Matesanz N, Lafuente N, Azcutia V, et al. Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-jun N-terminal kinase and p38 mitogen-activated protein kinases. J Hypertens. 2007;25:609–618
  9. Callsen D, Sandau KB, Brune B. Nitric oxide and superoxide inhibit platelet-derived growth factor receptor phosphotyrosine phosphatases. Free Radic Biol Med. 1999;26:1544–1553
  10. Marumo T, Schini-Kerth VB, Fissithaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation. 1997;96:2361–2367
  11. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-κB and IκB system in smooth muscle cells after rat arterial injury. Am J Pathol. 1997;151:1085–1095
  12. Miyake T, Aoki M, Shiraya S, et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol. 2006;41:431–440
  13. Orlandi A, Francesconi A, Marcellini M, di Lascio A, Spagnolli LG. Propionyl-l-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intima smooth muscle cells by modulating nuclear factor-κB activity. J Biol Chem. 2007;282:4932–4942
  14. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539–545
  15. Ueno H, Kanellakis P, Agrotis A, Bobik A. Blood flow regulates the development of vascular hypertrophy, smooth muscle cell proliferation and endothelial cell nitric oxide synthase in hypertension. Hypertension. 2000;36:89–96
  16. Brar SS, Kennedy TP, Sturrock AB, et al. NADPH oxidase promotes NF-kappaB activation and proliferation in human airway smooth muscle. Am J Physiol. 2002;282:L782–L795
  17. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene. 2003;22:8961–8982
  18. Leskinen MJ, Heikkila HM, Speer MY, et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-κB-mediated survival signalling. Exp Cell Res. 2006;312:1289–1298
  19. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther. 2002;300:393–398
  20. Peng T, Lu X, Feng Q. NADH oxidase signalling induces cyclooxygenase-2 expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB J. 2005;19:293–295
  21. Rious N, Castonguay A. The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-κB. Carcinogenesis. 2000;21:1745–1751
  22. Koyama H, Reidy MA. Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2. Circ Res. 1997;80:408–417
  23. Szocs K, Lassegue B, Sorescu D, et al. Upregulation of nox-based NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler Thromb Vasc Biol. 2002;22:21–27
  24. Miller FJ, Filali M, Huss GJ, et al. Cytokine activation of nuclear factor kappaB in vascular smooth muscle cells requires signaling endosomes containing Nox1 and CIC-3. Circ Res. 2007;101:663–671
  25. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–5799
  26. Usui M, Egashira K, Ohtani K, et al. Anti-monocyte chemoattractant protein-1 therapy inhibits restenotic changes (neointima hyperplasia) after balloon injury in rats and monkeys. FASEB J. 2002;16:1838–1840
  27. Jay DB, Papaharalambus A, Seidel-Rogol B, Dikalova AE, Lassegue B, Griendling KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med. 2008;45:329–335
  28. Haysahi K, Takahata H, Kitagawa n , Kitange G, Kaminogo M, Shibata S. N-acetylcysteine inhibited nuclear factor-kappaB expression and the intimal hyperplasia in rat carotid arterial injury. Neurol Res. 2001;23:731–738
  29. Ueberla K, Lu Y, Chung E, Haseltine WA. The NF-kappa B p65 promoter. J Acquir Immune Defic Syndr. 1993;6:227–230
  30. Ahn KS, Sethi G, Krishnan K, Aggarwal BB. γ-Tocotrienol inhibits nuclear factor-κB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem. 2007;282:809–820
  31. Andres V, Castro C. antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol. 2003;1:85–98
  32. Younes A, Ayoub JP, Sarris A, et al. Paclitaxel activity for the treatment of non-Hodgkin’s lymphoma: final report of a phase II trial. Br J Haematol. 1997;96:328–332
  33. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  34. Jeremias A, Dusa C, Forudi F, et al. N-acetyl-cysteine in the prevention of vascular restenosis after percutaneous balloon angioplasty. Int J Cardiol. 2004;95:255–260
  35. Suzuki J, Iwai M, Mogi M, et al. Epleronone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917–921
  36. Cuaz-Perolin C, Billiet L, Bauge E, et al. Antiinflammatory and antiatherogenic effects of the NF-κB inhibitor acetyl-11-keto-β-boswellic acid in LPS-challenged ApoE−/− mice. Arterioscler Thromb Vasc Biol. 2008;28:272–277

PII: S0021-9150(08)00624-2

doi: 10.1016/j.atherosclerosis.2008.09.005

Atherosclerosis
Volume 204, Issue 1 , Pages 66-72 , May 2009

Article Tools

* Image Usage & Resolution